LifeStance Health Group (NASDAQ:LFST – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $10.00 price target on the stock. Morgan Stanley’s price target points to a potential upside of 70.36% from the stock’s previous close.
A number of other research firms also recently weighed in on LFST. Barclays lifted their price target on shares of LifeStance Health Group from $7.00 to $8.00 and gave the company an “underweight” rating in a research report on Thursday, February 29th. The Goldman Sachs Group lifted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Monday, March 4th. Finally, Jefferies Financial Group lifted their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, LifeStance Health Group presently has an average rating of “Hold” and a consensus target price of $8.83.
Read Our Latest Research Report on LFST
LifeStance Health Group Stock Performance
Shares of LFST stock traded up $0.16 on Monday, reaching $5.87. The stock had a trading volume of 1,071,433 shares, compared to its average volume of 1,306,499. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.20. The firm’s 50-day moving average is $6.48 and its two-hundred day moving average is $6.54. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -11.51 and a beta of 1.34. LifeStance Health Group has a 12 month low of $4.74 and a 12 month high of $9.59.
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The firm had revenue of $280.60 million during the quarter, compared to the consensus estimate of $263.14 million. LifeStance Health Group had a negative net margin of 17.64% and a negative return on equity of 12.66%. On average, research analysts expect that LifeStance Health Group will post -0.3 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, insider Danish J. Qureshi sold 12,965 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $5.93, for a total value of $76,882.45. Following the sale, the insider now owns 4,911,050 shares of the company’s stock, valued at $29,122,526.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Danish J. Qureshi sold 12,965 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $5.93, for a total value of $76,882.45. Following the sale, the insider now owns 4,911,050 shares of the company’s stock, valued at $29,122,526.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Kevin Michael Mullins sold 115,136 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $8.02, for a total transaction of $923,390.72. Following the completion of the transaction, the insider now owns 4,575,480 shares in the company, valued at approximately $36,695,349.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 245,463 shares of company stock valued at $1,786,868. 8.50% of the stock is currently owned by insiders.
Hedge Funds Weigh In On LifeStance Health Group
Several hedge funds and other institutional investors have recently bought and sold shares of LFST. DekaBank Deutsche Girozentrale acquired a new position in shares of LifeStance Health Group during the third quarter valued at about $34,000. Sunbelt Securities Inc. acquired a new position in shares of LifeStance Health Group during the third quarter valued at about $34,000. WESPAC Advisors LLC acquired a new position in shares of LifeStance Health Group during the third quarter valued at about $90,000. Stratos Wealth Partners LTD. acquired a new position in shares of LifeStance Health Group during the fourth quarter valued at about $93,000. Finally, Assetmark Inc. raised its holdings in shares of LifeStance Health Group by 21.6% during the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock valued at $93,000 after purchasing an additional 2,114 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.
About LifeStance Health Group
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Recommended Stories
Before you consider LifeStance Health Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and LifeStance Health Group wasn’t on the list.
While LifeStance Health Group currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.
Source: marketbeat.com
